Autolus Therapeutics dismisses EY UK and appoints EY US as independent auditor

Autolus Therapeutics plc

Audit committee dismissed EY UK on April 14, 2026; no disagreements or reportable events in prior two fiscal years.
Audit committee appointed EY US as new independent auditor for FY 2026, effective immediately.
EY UK's audit reports for 2024 and 2025 were unqualified; prior material weakness in internal controls disclosed in Q1 2024 10-Q.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.